纖維瘤市場規模、佔有率和成長分析：按類型、療法、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球纖維瘤市場價值為 29.1 億美元，預計到 2025 年將成長至 31.1 億美元，到 2033 年將成長至 53 億美元，在預測期（2026-2033 年）內複合年成長率為 6.9%。

全球纖維瘤市場專注於治療、診斷和手術干預，以應對這種罕見癌症。纖維瘤僅佔所有癌症的一小部分。切除後高復發率這項重大挑戰嚴重影響患者的生活品質，迫使醫療機構和保險公司加強資源配置。傳統的治療方法主要依賴手術切除和放射療法，但蛋白酪氨酸激酶抑制劑等藥物的出現極大地改變了治療策略。人們對遺傳因素的認知不斷提高，促進了研究經費的投入和臨床試驗參與度的提升。市場促進因素包括孤兒藥的監管獎勵措施，促使製藥投資激增，創新療法層出不窮。這些不斷變化的市場環境也刺激了對磁振造影（MRI）和基因檢測的需求，為這個細分市場創造了新的商機，並推動了個人化影像解決方案的發展。

全球纖維瘤市場成長要素

醫學界對纖維瘤的認知不斷提高，促進了非典型症狀的早期發現、快速轉診至專科治療中心以及及時實施有效治療策略，從而推動了市場發展。這種臨床認知的提高減少了診斷延誤，改善了患者管理，進而提高了臨床試驗的參與率，並擴大了治療選擇。此外，臨床醫師對多學科診療的抗拒情緒降低，促進了協作治療方案的製定，從而改善了全球患者的治療效果。因此，這些因素共同推動了纖維瘤市場的發展，促進了現有療法和新型療法的應用。

全球纖維瘤市場中的限制因素

由於纖維瘤的罕見性和不可預測性，全球纖維瘤市場面臨嚴峻挑戰，難以進行大規模隨機對照試驗。因此，缺乏全面的證據支持治療方案的選擇，迫使臨床醫生依賴有限的病例報告和專家建議。這種不確定性往往會降低人們接受創新療法的意願，影響保險報銷核准，並阻礙對專業研究舉措的投資。監管機構對更多數據的要求可能會延長產品上市時間，所有這些因素共同限制了市場擴張，並縮小了患者獲得先進療法的機會。

全球纖維瘤市場趨勢

全球纖維瘤市場正經歷著向精準腫瘤學的重大轉變，這主要得益於分子譜分析和次世代定序技術的進步。臨床醫生擴大利用遺傳和表觀遺傳數據來實現個人化治療，並為患者匹配標靶治療，包括仿單標示外用藥。這種個人化方法在提高治療效果的同時，也最大限度地降低了患者接受多種治療的風險。產學合作的不斷深化正在加速開發便利的診斷平台，並推動其在三級醫療機構的早期應用。這種向實證個體化醫療的轉變有望改善患者預後，並重新定義纖維瘤的標準治療方案。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球纖維瘤市場規模：按類型分類

• 腹膜內纖維瘤
• 腹壁纖維瘤
• 腹膜外纖維瘤

全球纖維瘤市場規模：依治療類型分類

• 主動後續觀察（嚴密監視）
• 藥物治療
  • γ-分泌酶抑制劑
  • 蛋白酪氨酸激酶抑制劑（TKIs）
  • 非類固醇消炎劑（NSAIDs）
  • 荷爾蒙療法
  • 化療
  • 其他
• 外科手術
• 放射線治療
• 其他

全球纖維瘤市場規模：依最終用戶分類

• 醫院
• 腫瘤中心
• 專科診所
• 學術研究機構

全球纖維瘤市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 專科藥房

全球纖維瘤市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• SpringWorks Therapeutics, Inc.
• ImmunityBio, Inc.
• Iterion Therapeutics, Inc.
• Deciphera Pharmaceuticals, LLC
• Daiichi Sankyo Company, Limited
• Pfizer Inc.
• Bayer AG
• AbbVie Inc.
• Amgen Inc.
• Merck & Co., Inc.
• Ipsen SA
• Blueprint Medicines Corporation
• Exelixis, Inc.
• Karyopharm Therapeutics Inc.
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Johnson & Johnson
• Merck KGaA
• BeiGene, Ltd.
• Regeneron Pharmaceuticals, Inc.

結論與建議

Global Desmoid Tumors Market size was valued at USD 2.91 Billion in 2024 and is poised to grow from USD 3.11 Billion in 2025 to USD 5.3 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The global market for desmoid tumors is characterized by a focus on therapeutics, diagnostics, and surgical interventions for this rare neoplasm, accounting for a minimal percentage of overall cancers. The notable challenge of high recurrence rates post-resection significantly impacts patient quality of life, prompting healthcare providers and insurers to enhance resource allocation. Historically reliant on surgical excision and radiation, advancements such as tyrosine-kinase inhibitors have transformed treatment approaches. Growing awareness of genetic factors has catalyzed increased research funding and trial participation. Key market drivers include regulatory incentives for orphan drugs, leading to pharmaceutical investments and a surge in innovative therapies. This evolving landscape is also stimulating demand for MRI and genetic testing, creating new revenue opportunities and fostering tailored imaging solutions in this niche market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Desmoid Tumors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Desmoid Tumors Market Segments Analysis

Global desmoid tumors market is segmented by type, treatment type, end user, distribution channel and region. Based on type, the market is segmented into intra-abdominal desmoid tumors, abdominal wall desmoid tumors and extra-abdominal desmoid tumors. Based on treatment type, the market is segmented into active surveillance (watchful waiting), drug therapy, surgery, radiation therapy and others. Based on end user, the market is segmented into hospitals, oncology centers, specialty clinics and academic & research institutes. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and specialty pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Desmoid Tumors Market

Growing awareness of desmoid tumors within the medical community is driving the market forward by facilitating early detection of atypical symptoms, prompt referrals to specialized treatment centers, and the timely implementation of effective therapeutic strategies. This heightened clinical awareness reduces diagnostic delays and enhances patient management, leading to increased participation in clinical trials and a broader range of treatment options. Furthermore, the rising comfort among clinicians in discussing multidisciplinary care fosters coordinated treatment planning, resulting in improved management outcomes for patients globally. Consequently, these factors collectively contribute to the expansion of the desmoid tumors market through enhanced use of both existing and novel therapies.

Restraints in the Global Desmoid Tumors Market

The global market for desmoid tumors faces significant challenges due to the rarity and unpredictable nature of these tumors, which complicates the execution of large-scale randomized trials. This results in a scarcity of comprehensive evidence to support therapeutic choices, leading clinicians to rely on limited case series or expert recommendations. Such uncertainty often undermines the willingness to embrace innovative treatments, while also impacting the approval of reimbursement and deterring investment in focused research initiatives. These factors collectively restrict market expansion and diminish patient access to advanced therapies, as regulatory authorities may demand further data, prolonging the timelines for product launches.

Market Trends of the Global Desmoid Tumors Market

The Global Desmoid Tumors market is experiencing a significant shift towards precision oncology, driven by advancements in molecular profiling and next-generation sequencing technologies. Clinicians are increasingly leveraging genetic and epigenetic data to tailor treatments, matching patients with targeted therapies, including those used off-label. This personalized approach enhances treatment efficacy while minimizing patients' exposure to broad-spectrum interventions. The rise of academic-industry collaborations is facilitating the development of accessible diagnostic platforms, fostering early adoption in tertiary care centers. This transition towards evidence-based, personalized care is expected to improve patient outcomes and redefine standard treatment protocols in the management of desmoid tumors.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Desmoid Tumors Market Size by Type & CAGR (2026-2033)

• Market Overview
• Intra-Abdominal Desmoid Tumors
• Abdominal Wall Desmoid Tumors
• Extra-Abdominal Desmoid Tumors

Global Desmoid Tumors Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Active Surveillance (Watchful Waiting)
• Drug Therapy
  • Gamma-Secretase Inhibitors
  • Tyrosine Kinase Inhibitors (TKIs)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Hormonal Therapy
  • Chemotherapy
  • Others
• Surgery
• Radiation Therapy
• Others

Global Desmoid Tumors Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Oncology Centers
• Specialty Clinics
• Academic & Research Institutes

Global Desmoid Tumors Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies

Global Desmoid Tumors Market Size & CAGR (2026-2033)

• North America (Type, Treatment Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Treatment Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment Type, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• SpringWorks Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ImmunityBio, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Iterion Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Deciphera Pharmaceuticals, LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Blueprint Medicines Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations